Esperion Therapeutics, Inc. (ESPR)
| Market Cap | 804.47M +348.4% |
| Revenue (ttm) | 418.24M +61.1% |
| Net Income | -7.42M |
| EPS | -0.03 |
| Shares Out | 257.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,258,695 |
| Open | 3.130 |
| Previous Close | 3.130 |
| Day's Range | 3.120 - 3.140 |
| 52-Week Range | 0.693 - 4.175 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | 5.72 (+83.04%) |
| Earnings Date | May 7, 2026 |
About ESPR
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its product... [Read more]
Financial Performance
In 2025, Esperion Therapeutics's revenue was $403.14 million, an increase of 21.31% compared to the previous year's $332.31 million. Losses were -$22.68 million, -56.17% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price target is $5.72, which is an increase of 83.04% from the latest price.
News
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric Phase 2 Stud...
Esperion downgraded to Hold from Buy at Needham
Needham downgraded Esperion (ESPR) to Hold from Buy after the company announced it will be acquired by Archimed for $3.16 per share and a $100M contingent value right. Published first…
Esperion downgraded to Hold from Buy at Jefferies
Jefferies downgraded Esperion (ESPR) to Hold from Buy with a price target of $3.28, down from $5, after the company announced it will be acquired by Archimed for $3.16 per…
Esperion downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler downgraded Esperion (ESPR) to Neutral from Overweight with a price target of $3.16, down from $9, after funds managed by Archimed announced a deal to acquire Esperion for…
Esperion downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Esperion (ESPR) to Neutral from Buy with a $3.16 price target after the company agreed to be acquired by investment firm Archimed for for $3.16 per share.
Esperion downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald downgraded Esperion (ESPR) to Neutral from Overweight with a $3.16 price target after funds managed by Archimed announced a deal to acquire Esperion for $3.16 per share in…
Archimed to take Esperion Therapeutics private in $1.1 billion deal
Investment firm Archimed will take Esperion Therapeutics private for up to $1.1 billion, the companies said on Friday, sending the drugmaker's shares up over 55% in premarket trading.
Esperion to be acquired by Archimed for $3.16 per share, one CVR
Esperion (ESPR) and Archimed announced that they have entered into a definitive agreement under which funds managed by Archimed will acquire Esperion in a transaction valued at up to approximately…
Esperion to be Acquired by ARCHIMED
Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments
Esperion to Report First Quarter 2026 Financial Results on May 7
ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026.
Esperion Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Significant revenue growth and strategic expansion were highlighted, including the acquisition of Corstasis and the upcoming launch of Enbumyst for heart failure. Updated treatment guidelines and international launches are expected to drive further growth, while pipeline advancements and manufacturing improvements support long-term profitability.
Esperion, Athyrium Capital enter $50M royalty financing agreement
Athyrium Capital and Esperion (ESPR) announced the entry into a $50M royalty financing agreement under which certain funds managed by Athyrium Capital Management will acquire 100% of Esperion’s royalt...
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
NEW YORK and ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Athyrium Capital Management, LP and Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the entry into a $50 million royalty fi...
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued...
Esperion showcases new data from CLEAR Outcomes trial
Esperion (ESPR) announced the presentation of two post-hoc analyses from the CLEAR Outcomes trial focused on the risk of ischemic stroke and major adverse cardiovascular events, or MACE, in patients…
Esperion says bempedoic acid receives recommendations in ACC/AHA Guideline
Esperion (ESPR) welcomed the inclusion of bempedoic acid for LDL-C lowering and cardiovascular risk reduction in the 2026 Americal College of Cardiology/American Heart Association Multisociety Guideli...
Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolem...
Esperion price target raised to $5 from $4 at Citizens
Citizens raised the firm’s price target on Esperion (ESPR) to $5 from $4 and keeps an Outperform rating on the shares. Esperion reported Q4 results consistent with the preannouncement in…
Esperion Therapeutics Transcript: The Citizens Life Sciences Conference 2026
Options Volatility and Implied Earnings Moves Today, March 10, 2026
Today, several major companies are expected to report earnings: AeroVironment (AVAV), Franco-Nevada (FNV), Groupon (GRPN), Kohl’s (KSS), Oracle (ORCL), Uranium Energy (UEC), Esperion (ESPR), Nio (NIO)...
Esperion Therapeutics Earnings Call Transcript: Q4 2025
Record 2025 results featured 144% revenue growth, strong cash position, and major international expansion. The Corstasis acquisition and upcoming U.S. guideline inclusion are set to accelerate growth and broaden the cardiometabolic portfolio.
Esperion reports Q4 EPS 22c, consensus 28c
Reports Q4 revenue $168.4M, consensus $166.12M. “2025 was a defining year for Esperion (ESPR). We delivered strong growth in our U.S. cardiovascular franchise, broadened access and adoption among stat...
Esperion sees 2026 operating expenses $225M-$255M vs. $343M in 2025
06:03 EDT Esperion (ESPR) sees 2026 operating expenses $225M-$255M vs. $343M in 2025
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –
Esperion Therapeutics Transcript: M&A announcement
The acquisition of Corstasis and ENBUMYST expands the cardiovascular portfolio, leveraging existing infrastructure to address a $4+ billion heart failure market. The deal includes $75M upfront, milestones, and royalties, with strong IP and a differentiated product expected to drive growth and reduce hospitalizations.